Skip to Content

Tobramycin Sulfate Injection

Last Updated: March 8, 2019
Status: Current

Products Affected - Description
    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 2 mL vial, 25 count, NDC 17478-0114-02 - discontinued
    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 30 mL vial, 1 count, NDC 17478-0114-30 - discontinued
    • Tobramycin Sulfate solution for injection, Baxter (formerly Claris), 40 mg/mL, 2 mL vial, 25 count, NDC 36000-0244-25
    • Tobramycin Sulfate solution for injection, Baxter (formerly Claris), 40 mg/mL, 30 mL vial, 1 count, NDC 36000-0242-01
    • Tobramycin Sulfate solution for injection, Mylan Institutional, 40 mg/mL, 2 mL vial, 25 count, NDC 67457-0473-22
    • Tobramycin Sulfate solution for injection, Mylan Institutional, 40 mg/mL, 30 mL vial, 10 count, NDC 67457-0428-30
    • Tobramycin Sulfate solution for injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-3578-01
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 2 mL vial, 25 count, NDC 00703-9402-04
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 30 mL vial, 1 count, NDC 00703-9416-01 - discontinued
Reason for the Shortage
    • Akorn discontinued tobramycin injection in late-2018.
    • Pfizer had tobramycin injection on shortage due to manufacturing delays.
    • Teva discontinued tobramycin 40 mg/mL 30 mL vials in June 2018.
Available Products
    • Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 63323-0303-51
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0305-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0306-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 30 mL vial, 10 count, NDC 63323-0306-30
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 50 mL vial, 1 count, NDC 63323-0307-51
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 1 count, NDC 39822-0412-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 39822-0412-06

Estimated Resupply Dates

    • Baxter (formerly Claris) has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company cannot estimate a release date.
    • Mylan Institutional has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company estimates a release date of mid-April 2019.
    • Pfizer has tobramycin 40 mg/mL 2 mL vials available in limited supply.
    • Teva has temporarily discontinued tobramycin 40 mg/mL 2 mL vials.

Updated

Updated March 8, 2019 by Megan Dryer, PharmD. Created May 28, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide